Show Display Options
Rank Status Study
1 Completed Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia
Conditions: Atherosclerosis;   Cardiovascular Diseases;   Heart Diseases;   Hypercholesterolemia;   Hyperlipidemia, Familial Combined
2 Completed Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals
Conditions: Hyperlipidemia, Familial Combined;   Coronary Disease
3 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia
Condition: Hyperlipidemia, Familial Combined
Interventions: Drug: Atorvastatin 20mg;   Drug: Omega-3-acids ethylesters 90 4g;   Other: Placebo(Omega-3-acids ethylesters 90)
4 Completed Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
Conditions: Atherosclerosis;   Leukocyte Activation Disorder;   Type 2 Diabetes Mellitus;   Familial Combined Hyperlipidemia
Intervention: Dietary Supplement: OGTT
5 Completed Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol
Conditions: Hypercholesterolemia;   Hyperlipidemia, Familial Combined
Interventions: Drug: colesevelam HCl tablets and fenofibrate tablets;   Drug: fenofibrate tablets and Welchol placebo tablets
6 Completed Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism
Conditions: Metabolic Syndrome;   Familial Hypertriglyceridemia;   Familial Combined Hyperlipidemia
Interventions: Drug: chenodeoxycholic acid;   Drug: placebo capsules
7 Completed Genetic Epidemiology of Hypertriglyceridemia
Conditions: Cardiovascular Diseases;   Coronary Disease;   Hyperlipidemia, Familial Combined;   Hyperlipoproteinemia Type iv
8 Completed Genomic Dissection of a QTL Affecting the Lipid Profile
Conditions: Cardiovascular Diseases;   Heart Diseases;   Obesity;   Hyperlipidemia, Familial Combined
9 Completed Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification
Condition: Cardiovascular Disease
10 Completed A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
Conditions: Hyperlipidemia;   Hypercholesterolemia;   Hypertriglyceridemia
Intervention: Drug: ezetimibe (+) simvastatin
11 Completed Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
Conditions: Hyperlipidemia;   Mixed Hyperlipidemia;   Dyslipidemia
Intervention: Drug: Niacin Extended Release/Lovastatin
12 Completed Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Subjects With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: SCH 900271;   Drug: Placebo
13 Withdrawn Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Mixed Hyperlipidemia and Two or More Risk Factors
Conditions: Cardiovascular Diseases;   Hyperlipidemia
Interventions: Drug: ezetimibe/simvastatin 10/20 mg + placebo;   Drug: ezetimibe/simvastatin 10/20 mg + MK0524A
14 Completed Lipid Efficacy and Safety in Patients With Mixed Hyperlipidemia (MK-0524B-024)
Condition: Mixed Hyperlipidemia
Interventions: Drug: Comparator: MK0524B;   Drug: Comparator: Atorvastatin
15 Recruiting Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid
Condition: Mixed Hyperlipidemia
Interventions: Drug: Atorvastatin 10mg, fenofibric acid 135mg;   Drug: atorvastatin 20mg
16 Completed A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia
Conditions: Hypercholesterolemia;   Hyperlipidemia
Intervention: Drug: MK0859
17 Terminated Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
Condition: Mixed Hyperlipidemia
Interventions: Drug: torcetrapib/atorvastatin;   Drug: atorvastatin
18 Completed Lipid Efficacy Study
Conditions: Primary Hypercholesterolemia;   Mixed Hyperlipidemia
Interventions: Drug: niacin (+) laropiprant (+) simvastatin;   Drug: Comparator: niacin (+) laropiprant;   Drug: Comparator: simvastatin
19 Recruiting A Pilot Study to Evaluate the Lipid Effects of TRIA-662
Conditions: Hypertriglyceridemia;   Mixed Hyperlipidemia
Interventions: Drug: TRIA-662;   Drug: Placebo
20 Completed Lipid Efficacy/Tolerability Study (0524A-020)
Conditions: Primary Hypercholesterolaemia;   Mixed Hyperlipidaemia
Interventions: Drug: niacin (+) laropiprant;   Drug: ER-niacin

Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results
Indicates status has not been verified in more than two years